A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma

Part of paid clinical trials in Birmingham, Alabama.

Sponsor
Janssen Research & Development, LLC
Study ID
NCT05050097
Phase
PHASE1
Status
Active Not Recruiting

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Talquetamab — DRUG
    Talquetamab will be administered subcutaneously.
  • Carfilzomib — DRUG
    Carfilzomib will be administered as an IV infusion.
  • Daratumumab SC — DRUG
    Daratumumab will be administered subcutaneously.
  • Lenalidomide — DRUG
    Lenalidomide will be self-administered orally.
  • Pomalidomide — DRUG
    Pomalidomide will be self-administered orally.

Study Details

The purpose of this study is to characterize the safety and tolerability of talquetamab when administered in different combination regimens and to identify the safe dose(s) of talquetamab combination regimens.

Key Dates

Start date
Sep 22, 2021
Status verified
Jun 2026
Primary completion
Mar 31, 2025
Completion
Oct 13, 2027

Study Design

Enrollment
166 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Treatment Regimen A: Talquetamab + Carfilzomib
    Participants assigned to Treatment regimen A will receive talquetamab subcutaneously (SC) in combination with carfilzomib as an intravenous (IV) infusion.
  • Experimental: Treatment Regimen B: Talquetamab + Daratumumab + Carfilzomib
    Participants assigned to Treatment regimen B will receive talquetamab SC in combination with daratumumab SC and carfilzomib as an IV infusion.
  • Experimental: Treatment Regimen C: Talquetamab + Lenalidomide
    Participants assigned to Treatment regimen C will receive talquetamab SC in combination with lenalidomide orally.
  • Experimental: Treatment Regimen D: Talquetamab + Daratumumab + Lenalidomide
    Participants assigned to Treatment regimen D will receive talquetamab SC in combination with daratumumab SC and lenalidomide orally.
  • Experimental: Treatment Regimen E: Talquetamab + Pomalidomide
    Participants assigned to Treatment regimen E will receive talquetamab SC in combination with pomalidomide orally.

Primary Outcome Measure

Number of Participants with Adverse Events (AEs) as a Measure of Safety and Tolerability [ Time Frame: Up to 1 year and 10 months ]

Locations (12)

FacilityCityStateZIPSite coordinators
University of Alabama BirminghamBirminghamAlabama35294-
University of California San FranciscoSan FranciscoCalifornia94143-
Colorado Blood Cancer InstituteDenverColorado80218-
Emory UniversityAtlantaGeorgia30322-
Indiana UniversityIndianapolisIndiana46202-
Hackensack University Medical CenterHackensackNew Jersey07601-
Mt. Sinai School of MedicineNew YorkNew York10029-
Weill Cornell Medical CollegeNew YorkNew York10065-
Levine Cancer InstituteCharlotteNorth Carolina28204-
University of Pittsburgh Medical CenterPittsburghPennsylvania15232-
Tennessee OncologyNashvilleTennessee37203-
Medical College Of WisconsinMilwaukeeWisconsin53226-

Find similar trials in Birmingham, AL

By condition
Multiple myeloma
By specialty
OncologyBlood cancer
By research site
University of Alabama Birmingham· Birmingham, ALUniversity of California San Francisco· San Francisco, CAColorado Blood Cancer Institute· Denver, COEmory University· Atlanta, GAIndiana University· Indianapolis, INHackensack University Medical Center· Hackensack, NJ

Related Studies